The medicine is intended to be used by individuals who have anodontia, a congenital condition that causes people to not grow a full set of teeth.
The lead researcher for the team is Katsu Takahashi, who is also the head of the dentistry and oral surgery department at the Medical Research Institute Kitano Hospital in Osaka, Japan.
The research team hopes to have the medicine ready for general public use in 2030 and will be mostly used to treat children aged 2 to 6, the report said.